Imagine trying to find a key for five different locked doors, but discovering they all actually use the same type of lock. This project uses AI and lab-grown muscle cells to find existing medicines that can be reused to treat several rare muscle diseases at once. It's like finding a multi-purpose tool that fixes many different problems instead of building a new tool for every single one.
Less than 6% of rare diseases have approved treatments because traditional drug development is too slow and expensive for small patient populations.
An AI-powered drug repurposing pipeline and a lab-grown muscle cell screening system to identify shared drug targets across multiple rare diseases.
If you are a drug discovery firm dealing with the high cost of developing new molecules — this project developed an AI-based screening process that reduces small molecule identification timelines from 3-5 years to 12 months.
If you are a biotech SME dealing with limited patient populations for clinical trials — this project developed an adaptive clinical trial design that targets common mechanisms across 5 different diseases to expand the treatable patient base.
If you are a diagnostics company dealing with a lack of reliable disease markers — this project developed up to 5 novel biomarkers for neuromuscular disorders to improve patient stratification.
The project aims to lower drug development costs by 40% by using AI and drug repurposing to identify existing candidates rather than starting from scratch.
Yes, the project includes a third AI-based solution specifically designed to find additional diseases that could be treated through shared drug targets, creating a reusable platform for rare diseases in general.
Based on available project data, the consortium aims to establish 3–5 industry agreements in rare NMDs within 3–5 years post-project.
DREAMS is designing an adaptive clinical trial and a regulatory-ready framework to create a pathway for drugs that treat heterogeneous groups of patients with rare diseases.
The long-term goal, extending beyond 5 years, is to deliver one clinically validated therapy.
The consortium is well-balanced for commercialization, featuring a 30% industry ratio with 3 industrial partners and 3 SMEs. With 10 partners across 6 countries (including the UK, France, and Israel), it combines academic research with the operational capacity of SMEs, coordinated by a specialized stem cell research center.
Contact the Centre d'Etude des Cellules Souches in France
Contact us to explore licensing opportunities for the AI drug screening platform.
